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Abstract 
In Lonza BiologicsÕ GS Gene Expression Systemª, recombinant protein-producing GS-
CHOK1SV cell lines are generated by transfection with an expression vector encoding both GS 
and the protein product genes followed by selection in MSX and glutamine-free medium.  MSX 
	 2 
is required to inhibit endogenous CHOK1SV GS, and in effect create a glutamine auxotrophy in 
the host that can be complemented by the expression vector encoded GS in selected cell lines.  
However, MSX is not a specific inhibitor of GS as it also inhibits the activity of GCL (a key 
enzyme in the glutathione biosynthesis pathway) to a similar extent.  Glutathione species (GSH 
and GSSG) have been shown to provide both oxidizing and reducing equivalents to ER-resident 
oxido-reductases, raising the possibility that selection for transfectants with increased GCL 
expression could result in the isolation of GS-CHOKISV cell lines with improved capacity for 
recombinant protein production.  In this study we have begun to address the relationship 
between MSX supplementation, the amount of intracellular GCL subunit in and mAb 
production from a panel of GS-CHOK1SV cell lines.  We then evaluated the influence of 
reduced GCL activity on batch culture of an industrially relevant mAb-producing GS-
CHOK1SV cell line.  To the best of our knowledge, this paper describes for the first time the 
change in expression of GCL subunits and recombinant mAb production in these cell lines with 
the degree of MSX supplementation in routine subculture.  Our data also shows that partial 
inhibition of GCL activity in medium containing 75 µM MSX increases mAb productivity, and 
its more specific inhibitor BSO used at concentration of 80 µM in medium increases the specific 
rate of mAb production 8-fold and the concentration in harvest medium by 2-fold.  These 
findings support a link between the inhibition of glutathione biosynthesis and recombinant 
protein production in industrially relevant systems and provide a process-driven method for 
increasing mAb productivity from GS-CHOK1SV cell lines.  
 
1.0 Introduction 
CHO cells are the most widely utilized mammalian cell type for the commercial production of 
recombinant proteins
1
.  Currently, there are two major CHO cell-based expression systems used 
in the pharmaceutical industry: DHFR (dihydrofolate reductase)
2-3
 and GS (glutamine 
synthetase)
4
.  When using the DHFR gene as a selectable marker, selection occurs in the 
absence of the metabolites hypoxanthine and thymidine.  Gene amplification is accomplished 
	 3 
by exposing the cells to increased concentrations of MTX, which inhibits DHFR enzyme 
activity
5
. Alternatively, when using the GS gene a selectable marker, stable cell lines are 
selected through the ability of the product of an exogenous GS gene to complement a glutamine 
auxotrophy (brought about by the inhibition of endogenous GS during selection in glutamine-
free medium and MSX
4
).  Transfectants containing an integrated exogenous copy of the GS 
gene in an transcriptionally active locus are able to synthesize glutamine from glutamic acid, 
ammonia and ATP
1
 and thus survive selection.  In the GS Gene Expression Systemª, a tight 
genetic linkage between the transcription cassettes of GS selectable marker and genes of interest 
favors those recombinant cells where a co-integration event at an active locus has occurred.  
When using MSX as a positive selection pressure in CHO cells, 3 µM inhibits endogenous 
enzyme activity
6
, 25-50 µM improves selection stringency
7
 and 200 µM selects for gene 
amplification
8
.  Whilst bi-allelic GS knockout host cell lines have been constructed lacking 
endogenous glutamine synthetase (e.g. LonzaÕs GS Xceedª System), 25-50 µM MSX is still 




In addition to GS, MSX inhibits the activity of the enzyme GCL, which catalyzes the synthesis 
of reduced glutathione (GSH) from its precursor amino acids: glutamate, cysteine and glycine
10
. 
In mammalian cells, the rate of de novo GSH synthesis is determined by the availability of 
cysteine and expression of two distinct gene products encoding the subunits of the 
heterodimeric GCL complex
11-12
. The larger GCLc subunit (~75 kDa) contains the active site 
whilst the smaller GCLm subunit (~30 kDa) acts to increase the catalytic efficiency of the 
enzyme through its interaction with GCLc
13
.  Direct and indirect functional measurements of the 
amounts of intracellular GCL subunits demonstrate that GCLm limits GCL holoenzyme 
complex formation in most cell types and tissues
14
.  Thus, expression of GCLc and GCLm are 




GSH is synthesized in a reduced state as a linear tri-peptide, and as electrons are lost, two GSH 
molecules become linked by a disulfide bond to form oxidized glutathione (GSSG)
15
. When 
Hwang et al. determined the concentration of GSH and GSSG within hybridoma CRL-1606 
cells
16
, the ratio of reduced GSH to GSSG within the secretory pathway ranged from 1:3 to 3:1, 
whereas the overall cellular ratio ranged from 30:1 to 100:1, suggesting that the secretory 
pathway is more oxidative than that of the cytosol.  These findings, and the observation that 
GSSG concentrations in freshly prepared ER-derived microsomal vesicles are similar to those 
required for in vitro folding
17
, have supported the hypothesis that the cellular balance of GSH to 
GSSG influences, and is important in maintaining the correct cellular environment for protein 
folding.   
 
The mechanism by which glutathione interacts with the folding machinery remains poorly 




however this oxidation can occur independently of GSSG through Ero1p
19-21
. It has also been 
suggested that GSH might have a role for maintaining PDI and other oxido-reductases (e.g. 
Erp57) in a reduced state so that they can catalyze the reduction part of the isomerization 
reactions necessary to correct miss-paired disulfide bonds
22-23
. Recent data suggests that GSH 





The oxidation of PDI by Ero1 is thought to occur through disulfide 
exchange that results in the formation of reduced Ero1
26
.  Ero1p can be oxidized rapidly in the 
presence of flavin adenine dinucleotide (FAD) and oxygen, indicating that oxygen is the 
ultimate electron acceptor
27
.  The reactivation of Ero1p by molecular oxygen generates reactive 
oxygen species (ROS) in the ER which in recent models are buffered by GSH
28
.   
 
With regard to recombinant protein production in mammalian cell lines, any alteration in the 
amount of glutathione (either GSH or GSGG forms) could have dramatic consequences on 
folding of recombinant protein.  For example, it is known that larger pools of GSH have been 
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found in highly productive antibody producing DHFR-CHO cells
29
.  Additionally, it was found 
that lowering the amount of intracellular glutathione in tPA-producing CHO cell lines 
accelerates disulfide bond formation but does not lead to correct protein folding as the reduction 
of incorrectly paired disulfide bonds were compromised, preventing disulfide bond 
isomerization occurring
30
.  Here we investigate the intriguing possibility that MSX 
supplementation in GS-CHO cell line construction alters recombinant protein production 
capacity, through GCL activity, as this is of direct relevance to users of GS selection systems
9
.  
We initially used expression analysis to identify relationships between MSX supplementation, 
GCL subunit expression and mAb production in a GS-CHOK1SV cell line.  We then describe 
an approach to evaluate the influence of inhibition of GCL activity on batch culture of a mAb-
producing GS-CHOK1SV cell line derived from the industrially relevant CHOK1SV host.    
 
2 Materials and methods 
2.1 Reagents 
Chemicals were purchased from Sigma-Aldrich (Dorset, UK) and cell culture reagents were 
sourced from Gibco/ThermoFisher (Paisley, UK) unless otherwise stated.  DNA size markers, 
enzymes and PCR reagents were purchased from Promega (Hampshire, UK).  DNA and RNA 
extraction kits were purchased from Qiagen (West Sussex, UK).  Oligonucleotide primers were 
commercially synthesized by MWG-Biotech (Hertfordshire, UK). 
 
2.2 Cell Lines and Cell Culture  
GS-CHOK1SV cell lines expressing a model mouse-human chimeric IgG4 mAb, cB72.3, were 
supplied by Lonza Biologics Plc (Slough, UK).  The panel of twelve cell lines selected for this 
study exhibit a range of cell specific production rates (qmAb) and the time integral of viable cell 
concentrations (IVC) in fed batch suspension culture (Supplementary Table 1). All GS-
CHOK1SV cell lines were constructed as described in Porter et al
31
.  The generation of these 
cell lines is described in Porter et al.
31
 with the exception of LB01, Null 8, Z1 and Z14 which 
	 6 
were constructed during an internal study (unpublished).  Null 8 is a ÒnullÓ cell line which has 
been constructed using an empty GS vector.  GS-CHOK1SV cell lines were grown in CD-CHO 
medium in 100 mL shake flask suspension cultures at 37¡C in 5% CO2 (v/v in air) using a 
humidified shaking incubator rotating at 140 rpm.  Cell counting was performed daily with a 
ViCell instrument (Beckman Coulter) using settings designed for CHO cells supplied by the 
vendor.  IVC and qmAb were estimated as described in Porter et al.
31
.  PearsonÕs correlation 
coefficients (rxy) and two-tailed paired T-test statistical significance were calculated in 
Microsoft Excel 2010. 
 
2.3 Gel migration assay 
10
6
 cells were pelleted from a suspension culture and were re-suspended in 1 mL PBS.  
Reduced and oxidized controls were generated by treating with either a final concentration of 10 
mM DTT or a final concentration of 1 mM dipyridyl sulfide, respectively.  The redox status of 
all samples was then trapped by alkylation of free thiols in a final concentration of 25 mM NEM 
followed by lysing the cells in 50 mM Tris-HCl containing 150 mM NaCl, 2 mM EDTA, 0.5 
mM phenylmethylsulfonyl fluoride, and 1% (v/v) Triton X-100.  The lysate was denatured by 
boiling for 2 min in the presence of 1% (w/v) SDS.  Tris[2-carboxyethyl]phosphine (TCEP) was 
added to a final concentration of 10 mM in order to reduce existing disulfide bonds, which were 
then alkylated by the addition of 30 mM AMS (Molecular Probes, Leiden, The Netherlands) for 
1 h at room temperature.  The lysates were separated by Bis Tris SDS-PAGE and subjected to 
western blot analysis in order to detect various oxido-reductases (section 2.4). 
 
2.4 Gel Electrophoresis and Western Blot Analysis 
Total protein was extracted from 10
7 
viable cells by the addition of RIPA buffer
32
.  Cells were 
washed twice with PBS and once with 0.35 M sucrose before the addition of the RIPA buffer.  
SDS-PAGE and western blot analysis was undertaken as previously described
33
 using the 
following antibodies and dilutions: GCLm (AB40929, Abcam), GCLc (AB17926 Abcam, 
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Cambridgeshire, UK), GS (G2781, Sigma, Dorset, UK), ERo1-Lα (PA146120 Affinity 
Biosystems, UK) 1:1000 and β-actin (A5441, Sigma, Dorset, UK) 1:10,000.  Western blots 
were developed using an enhanced chemiluminescence system (ECL, GE Healthcare) exposed 
to hyperfilm (GE Healthcare) and scanned using a GE-800 image scanner (GE Healthcare). 
 
2.5 Quantitative Real Time PCR Analysis of mRNA Levels 
Quantitative real-time PCR (qRT-PCR) was performed using an IQ5 instrument (Bio-Rad, UK) 
and the iScript One-Step RT-PCR Kit (Bio-Rad, UK) as described by Marchant et al.,
34
 using 
the following primers; GCLm Forward 5Õ-gtcagggagtttccagat-3Õ, Reverse 5Õ-
gtcagggagtttccagat-3Õ; GCLc Forward 5Õ-ccaattgttatggctttgagtgc-3Õ, Reverse 5Õ-
ccaattgttatggctttgagtgc-3Õ and values were normalized against TAF-7 (Forward 5Õ-
cgactccctagaacatgatgaa-3, Reverse 5Õ-gatcttctcggtgtcga-3Õ), β-actin and YWHAZ (primers 
supplied by Primer Design, UK).  These three genes had been selected from a panel of the ten 
housekeeping genes using geNorm
TM
 selection software (Primer Design, UK)
35
 and were 
deemed to exhibit the most stable expression in the GS-CHO cell lines analyzed in the study.  
 
2.6 Determination of Recombinant Chimeric IgG4 mAb Concentration 
The concentration of mAb in cell culture supernatant was determined by quantitative Protein A 
HPLC
31
.  Clarified supernatants were loaded onto a Poros Protein A immunodetection column, 
connected to an Agilent 1100 HPLC.  The column was washed and bound IgG was eluted, by 
lowering the pH of the solvent.  Eluted IgG was quantified using ChemStation software against 
a generic IgG standard.   
 
3.0 Results 
MSX lacks a high degree of specificity for GS; in vitro experiments have demonstrated as little 
as 50 µM is sufficient to inhibit purified sheep brain GS activity by 62% and purified rat kidney 
GCL activity by 85%
36  
.In this study we initially investigated the influence of MSX-based 
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supplementation (in selection and routine subculture) on the expression of endogenous GCL and 
mAb production in GS-CHOK1SV cell lines (section 3.1).  Subsequently, the effect of specific 
inhibition of GCL on the performance of a mAb-producing GS-CHOK1SV cell line was 
evaluated using the MSX analog BSO which lacks specificity for GS
37-38
 (section 3.2). 
 
3.1 GCL expression in GS-CHOK1SV cell lines 
In the GS expression Systemª, selection of transfectants derived from the CHOK1SV pool 
containing stably integrated copies of the GS selection marker linked to product-encoding genes 
is achieved through supplementation of glutamine-free medium with 25 µM MSX
9
.  As MSX 
also inhibits GCL activity, we initially hypothesized that GS-CHOK1SV cell lines selected in 
the presence of 50 µM MSX have also been selected with increased expression of endogenous 
GCL relative to the CHOK1SV host.   
 
Firstly, we compared GS and GCL expression (both mRNA and protein) to the amount of  
endogenous glutathione in CHOK1SV host cells (cultured in the absence of MSX) and seven 
mAb-producing GS-CHOK1SV cell lines
9
 (see Supplementary Table 1) selected in 50 µM 
MSX and cultured in glutamine-free medium supplemented with 25 µM MSX (Supplementary 
Figure 1).  Whilst GCL expression fluctuated between GS-CHOK1SV cell lines, the difference 
in the amount of GCL or glutathione between the CHOK1SV host and the GS-CHOK1SV cell 
lines was not statistically significant using the two-tailed paired T-test (Table 1).  In a subset of 
these seven cell lines (54, 114, 53, 142 and 38) we also measured endogenous glutathione 
concentrations, which were shown similar to that detected in the CHOK1SV host 
(Supplementary Figure 2).  This disproved our initial hypothesis, implying that these data do not 
support the theory that selection of GS-CHOK1SV cell lines in glutamine-free medium 
supplemented with 25 µM MSX influences the intracellular content of GCL and glutathione 
across these cell lines.   However, there is an inherent limitation in the comparison:  The host 
cell lines require medium supplement with 6 mM glutamine (to prevent the selection of host 
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cells with higher endogenous GS activity), whereas the mAb-producing cell lines are selected 
and cultured in glutamine-free medium (usually with MSX supplementation).  If glutamine was 
added to the medium used to select and culture the mAb-producing GS-CHOK1SV cell lines in 
order to make the medium similar to that used for the host, it would likely reduce selection 
pressure for the integration of exogenous GS and could result in cell line instability.  
Comparisons of a wider panel of CHO expression systems (e.g. DHFR, puromycin N-acetyl-
transferase and neomycin phosphotransferase selection markers) would perhaps be a better route 
to examine the influence of different selection conditions on GCL subunit expression.  However 
this would not be relevant to the CHOK1SV cell line. 
 
GS-CHOK1SV cell lines are routinely cultured in 25-50 µM MSX to maintain stable integration 
of the expression vector and/or stable expression of genes encoded by the vector
9
.  As 
previously discussed, these MSX concentrations are sufficient to inhibit purified rat kidney 
GCL activity
36
.  Therefore, we next investigated the relationship between MSX supplementation 
and endogenous GCL expression in routine subculture.  If indeed MSX supplementation results 
in inhibition of GCL activity, we expected expression of GCL subunits to be increased in order 
to compensate for the resulting glutathione depletion
12, 39
.  A rolling culture (i.e., defined as a 
regime of serial 96 h sub-cultures over a set number of cell generations) was completed for the 
mAb-producing GS-CHOK1SV cell line LB01 in duplicate 100 mL cultures supplemented with 
either 0, 25, 50 or 75 µM MSX.  Following 1344 h of subculture, the quantity of both GCL 
subunit mRNA and protein were determined by qRT-PCR and western blot analysis, 
respectively.  No correlation was evident between the concentration of MSX in the medium and 
the intracellular amount of GCLc mRNA (Figure 1A: rxy = -0.165).  However, a strong 
correlation between the concentration of MSX in the medium and the amount of intracellular 
GCLc protein was observed (Figure 1F: rxy= +0.889).  In contrast, the relationship between the 
GCLm subunit and the correlation of MSX concentration in the culture medium was stronger 
for mRNA (Figure 1B: rxy= +0.905) than for protein (Figure 1G: rxy= +0.359).  The magnitude 
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of change in GCL subunit expression (1.4 to 4-fold) was greater at ≥ 25 µM MSX. To the best 
of our knowledge, we believe that this is the first evidence that routine subculture of a mAb-
producing GS-CHOK1SV cell line in medium containing different concentrations of MSX 
influences the expression of endogenous GCL subunits.  
 
Following this, we asked the question: Are changes in the amount of GCL subunits with 
increasing MSX supplementation correlated with the specific production rate of the mAb 
(qmAb) and other cell culture parameters? To do this, fed-batch cultures of each mAb-
producing cell line were undertaken and subsequently the concentration of mAb in the harvest 
medium was determined by Protein A HPLC.  Data for GS-CHOK1SV cell lines Z1 and Z14 
(Supplementary Table 1), generated using in the same experiment, are presented in 
Supplementary Figure 3.  In the GS-CHOK1SV cell line LB01 the concentration of MSX 
supplementation correlated with IVC (Figure 2A: rxy = +0.681), qmAb (Figure 2B: rxy = +0.795) 
and the concentration of mAb in the harvest medium (Figure 2C: rxy = +0.988).  The expression 
of GCL mRNA and protein (Figure 1) was analyzed with respect to IVC, qmAb and mAb 
concentration in the harvest medium.  Only a weak correlation was observed between the 
amount of GCLc mRNA and either IVC (Figure 2D: rxy = +0.441), qmAb (Figure 2E: rxy = 
+0.567) or the mAb concentration in harvest medium (Figure 2F: rxy = +0.211).   In contrast, the 
amount of intracellular GCLc protein was more strongly correlated with the concentration of 
mAb in harvest medium (Figure 2I: rxy = +0.829) and less strongly correlated to IVC (Figure 
2G: rxy  = +0.617) and qmAb (Figure 2H: rxy = +0.589).  For GCLm, there was only a strong 
correlation between the mRNA and the concentration of mAb in the harvest medium (Figure 
2L: rxy: = +0.903) and less so for protein species (Figure 2O: rxy  = +0.359).  This inconsistency 
in the correlations of mRNA or protein for individual subunits with indicators of cell culture 
performance is probably the result of different regulation mechanisms.  Whilst a strong 
correlation was observed between the amount of GCLm mRNA or protein with qmAb (Figure 
2K: rxy = +0.844, Figure N: +0.708, respectively), a weak correlation was observed for IVC 
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(Figure 2J: rxy = +0.452, Figure 2M: rxy = +0.330, respectively).  Aside from this point, these 
data support a link between routine subculture in medium containing different concentrations of 
MSX and the ability of the GS-CHOK1SV cell lines to produce mAb. 
 
3.2 Effects of GCL inhibition on cB72.3 Production 
We next evaluated the effect of GCL inhibition on growth and productivity of a mAb-producing 
GS-CHOK1SV cell line.  As MSX inhibits both GS and GCL activity it is difficult to uncouple 
the influence of inhibition of each enzyme.  BSO is a synthetic analog that has specificity for 
GCL without any detectable inhibition of GS activity
37
.  Therefore, in contrast to our data 
obtained with MSX (section 3.1), any productivity change in response to BSO supplementation 
can be directly attributed to GCL activity.  The inhibition of GCL using BSO has been well 
characterized in CHO-K1 by Clark et al.
38
. and, therefore, their conditions were used as a 
starting point for our study.  Furthermore, to ensure that only endogenously derived GSH from 
the GCL pathway was available to the cell, the GS-CHOK1SV cell line used for this work (cell 
line 42, Supplementary Table 1) was adapted to and cultured in a medium lacking GSH and 
MSX.  100 mL cultures were supplemented with BSO at concentrations selected to give partial 
inhibition (i.e., 20 to 100 µM) together with enzyme-inhibitor saturation concentrations (i.e., 
250 µM to 5 mM) based on the data reported by Clark et al.
38
.  Cultures were incubated for 288 
h and viable cell concentration, viability and cell size were monitored.  Supernatant samples 
were removed at harvest (i.e., 288 h of culture time) for measurement of the concentration of 
mAb in the medium.   
 
Viable cell concentrations in cultures supplemented with BSO showed three different but 
distinct growth profiles throughout the 288 h batch suspension culture (Figure 3).  The 0 µM 
BSO culture (i.e., negative control) reached a maximal viable cell concentration of 6 x 10
6
 
cells/mL at 144 h culture time and a plateau for the remaining 144h.  Cultures supplemented 
with 20 to 100 µM BSO (i.e., partial inhibition) showed a similar growth profile, however the 
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maximum viable cell concentration was approximately 70% lower than the control culture 
(Figure 3).  Cultures treated with ≥ 250 µM BSO (i.e., enzyme-inhibitor saturation) did not 
enter exponential growth phase, and the majority of cultures had maximum viable cell 
concentration 85% lower than the control culture.  A sample of the culture treated 250 µM BSO 
was stained with DAPI and analyzed by immunofluorescence microscopy.  The results (data not 
shown) suggested that these cells were apoptotic, as determined from the observed chromatin 
condensation and cytoplasmic membrane blebbing as previously described by Arden and 
Betenbaugh
40
.  Figure 4 summarizes the effect of BSO supplementation on growth (A: mean 
cell diameter and B: IVC) and productivity (C: secreted cB72.3 concentration and D: qmAb).  
IVC declined with increased BSO supplementation (Figure 4B).  At conditions proposed to give 
partial inhibition (pa, Figure 4) of GCL (i.e., 20 to 100 µM BSO) a 2-fold increase in the 
concentration of mAb in the harvest medium was evident (Figure 4C) and this change correlated 
with either increased cell size (Figure 4A) (rxy: +0.721), increased qmAb (Figure 4D) (rxy: 
+0.865) or decreased IVC (Figure 4B) (rxy: -0.919).    These data suggest that at conditions 
proposed to give partial inhibition of GCL increased secreted concentrations of cB72.3 are 
achieved as a result of increased qmAb perhaps as the results of a cell cycle pause and at the 
expense of IVC.   
 
As the glutathione balance (GSH:GSSG) in the ER lumen is hypothesized to influence oxidative 
folding through a modulation oxido-reductases such as Ero1-L, we next determined the redox 
status of Ero1-Lα using a 1D-SDS-PAGE gel migration assay (see Methods) in cell samples 
derived from the batch cultures of cell line 42, which showed increased mAb production (Figure 
5: 20 and 100 µM BSO).  When cells were not treated with BSO, the Ero1-Lα protein migrated 
with the mobility of a reduced protein (Figure 5, DTT treated), demonstrating that Ero1-Lα is 
predominantly in a reduced form in the steady-state.  Treatment with BSO to reduce GCL 
activity resulted in the Ero1-Lα protein progressively moving towards a more oxidized state 
(Figure 5), as shown by the progressive decrease in gel migration distance of the Ero1-Lα band 
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with BSO concentration.  At the highest BSO concentration tested, the migration distance of 
Ero-1α tended to that of the oxidized DPS control.  However, a diffuse banding pattern was 
observed at ≥ 100µM, which is thought to represent heterogeneity due to a mixture of partial 
and fully oxidized forms of Ero1-Lα co-existing at the same time.  This is consistent with 
diffuse bands previously reported for PDI,  that were thought to represent two semi-oxidized 
forms in which either the first or second active site are oxidized
41
.  A shift of the steady-state 
from reduced to oxidized Ero1-Lα is aligned with increased mAb production in medium 
containing increasing concentrations (20-100 µM) of BSO.  We were unable to determine if this 
was the result of an indirect effect of BSO, or if a more oxidized Ero1-Lα accounts for the 2-3 
fold increase in mAb production.  
 
4.0 Discussion 
We postulated that CHOK1SV-derived GS cell lines constructed under MSX selection in the 
GS Expression Systemª
 
are more competent for recombinant protein expression, owing to 




GCLm mRNA and GCLc protein amounts are increased with MSX supplementation 
A positive relationship was observed between MSX supplementation concentrations and the 
amount of intracellular GCLm mRNA (Figure 1B).  A similar dose-dependent increase in 
GCLm has been demonstrated in HepG2/C3A cells with exposure to 50 µM to 0.3 mM MSX
14
.  
No correlation was evident between the concentration of MSX in medium and GCLc mRNA 
(Figure 1A).  Experiments performed in HepG2 and MCF7 mouse cell lines have demonstrated 
that GCLc mRNA is rapidly turned-over
42
 and perhaps suggest a tight control of expression in 
mammalian cell lines.  A strong correlation was observed between the concentration of MSX in 
the medium and the amount of GCLc protein (Figure 1F) which advocates a post transcriptional 
up-regulation GCLc protein expression in GS-CHOK1SV cell lines cultured in higher 
concentrations of MSX.  No such increase in GCLm protein was detected; however it is 
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plausible that observed increased amounts of mRNA (Figure 1B) are required to maintain 
steady-state concentrations of the GCLm subunit.   
 
The mechanism by which GCL expression is increased with MSX supplementation is likely to 
be indirect.  MSX binds to the glutamate active site of the GCL enzyme and in the presence of 




) and is converted to methionine sulfoximine phosphate 




We did not measure cellular glutathione and ROS 
concentrations in this experiment, however as de novo synthesis of glutathione is limited by 
GCL activity, we would expected that any inhibition will result in a lowering of GSH pools and 
result in an increased amount of oxidative species.  Both the intracellular concentrations of 
GCLc and GCLm, are positively regulated by transcription, mRNA turnover and post-
translation in response to oxidative stress
12
 which accounts for the increase in GCL mRNA and 
protein observed in GS-CHOK1SV cultures supplemented with MSX.  These experiments 
confirm that MSX-based selection interacts with systems aside from glutamine bio-synthesis.     
 
Inhibition of GCL activity increases mAb specific production rate and mAb concentration in 
harvest medium  
Partial inhibition of GCL activity in medium containing 75 µM MSX increases mAb 
productivity (Figure 2C), and its more specific inhibitor BSO used at concentration of 80 µM in 
medium increases the specific rate of mAb production 8-fold (Figure 4D) and the concentration 
in harvest medium by 2-fold (Figure 4C).  A similar increase in productivity from fed batch 
cultures has been reported when MSX was added to GS-knockout CHO IgG, producing clones 
generated in a MSX free process
43 
and this report did not identify any significant differences in 
gene copy number (GS and IgG) in the presence and absence of MSX treatment, suggesting that 
this increase is not the result of transgene amplification.  The treatment of tPA expressing CHO 
cells with 500 µM BSO for 16 hours has been reported to accelerate disulfide bond formation at 
the expense of non-native bond isomerization by using pulse chase experiments
29
.  Treatment of 
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cell-free extracts with BSO is standard practice and has been shown to increase the yield of an 
active model protein containing 9 disulfide bonds by 50%
44
.  In this study, at lower 
concentrations of BSO than that used by Oh et al
44
 (20 to 100 µM BSO), we observe an increase 
in secreted assembled mAb (measured by affinity for Protein A).  Similar reductions in cell 
growth leading to an increase in recombinant protein concentration in harvest medium have 
been reported in CHO when using a range of chemical compounds
45
.  Our data suggests that 
with lower concentrations of BSO (80 µM) or MSX (75 µM) benefits in terms of mAb 
production can be obtained but concentrations any higher are toxic, at least in the case of BSO.  
The findings of this and other internal unpublished studies performed in house have led us to 
investigate selection and maintenance of recombinant protein producing GS-CHOK1SV cell 
lines in glutamine free medium containing ≥50µM MSX .   
 
Increased mAb production is co-correlated with increased GCL expression, increased cell 
diameter and a shift from steady-state reduced to oxidized Ero1-Lα 
Increased mAb concentrations correlated with GCLc protein (Figure 2I) and GCLm mRNA 
(Figure 2L).  As previously discussed we predict that MSX supplementation will reduce the 
activity of GCL, deplete GSH pools, reducing the capacity for ROS buffering.  The presence of 
ER-localized ROS in mammalian cells generates an integrated stress response termed the 
UPR
46
, resulting in elevated glutathione synthesis
47
 and ER expansion
46
 which could explain the 
observed co-correlation between GCL subunits, mAb production and MSX supplementation. 
 
A strong positive correlation was observed between cell diameter and secreted cB72.3 
concentration (Figure 4A and 4C).  Depletion of glutathione with BSO has been shown to arrest 
cell division, suggesting that de novo glutathione synthesis is required for progression through 
the cell cycle and results in increased cell size
48
.  It has been reported that in CHO-K1-15500 
permanently producing tPA, cell size is a major determinant of productivity
49-50
. However, this 




.  Our data provides evidence that increased cell size, as a result of inhibition of 
glutathione synthesis, relates to increased cB72.3 production.  This further adds to the case for 
partial inhibition of glutathione pathways with BSO as a possible route to enrich populations 
with larger super producer clones and/or to the initial selection protocol.  
 
A shift of the Ero1-Lα from reduced to oxidized steady-state aligned with increased mAb 
production in medium containing increasing concentrations of BSO (20-100 µM).  As 
previously discussed Ero1Lα is thought to oxidize PDI, which in turn transfers oxidative 
equivalents to newly synthesized cargo proteins which directly contributes to disulfide bond 
formation
23
.  Therefore it is possible that a more oxidized Ero1 maintains PDI in a more active 
oxidative state which in turn could account for the 2-fold increase in mAb concentration we 
observed in the harvest medium. 
 
The report reaffirms the importance of glutathione biosynthesis as a potential route for 
enhancing recombinant CHO cell expression systems and highlights previously undefined ways 
that the GS system takes advantage of the promiscuity of MSX.  We initially set out to 
demonstrate that CHOK1SV-derived GS cell lines constructed under MSX selection in the GS 
Expression Systemª
 
are more competent for recombinant protein expression.  Whilst 
investigating this hypothesis we successfully demonstrated that specific inhibition of the GCL 
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Table I: Statistical analysis of normalized GCL mRNA and protein comparisons in CHO, 
N8 and cB72.3 expressing GS-CHOK1SV cell lines. CHO refers to the non-transfected 
CHOK1SV host and Null8 is a ÒnullÓ cell line constructed using an empty GS vector (see 
section 2.2).  mAb refers to cB72.3-producing GS-CHOK1SV cell lines (cell lines 41, 54, 114, 
53, 142, 147 and 38) 
 
Comparison 



























mRNA N/A 1.41 N/A 1.51 N/A N/A 
Protein  N/A 0.91 N/A 1.10 N/A 2.15 
CHO vs 
mAb 
mRNA 0.44 0.92 0.21 0.86 N/A N/A 
Protein 0.15 0.83 0.14 1.37 0.01 1.79 
CHO vs              
GS-CHO 
mRNA 0.92 0.98 0.75 0.94 N/A N/A 
Protein 0.14 0.85 0.16 1.33 0.01 1.85 
(a)
 two tailed paired T-test, 
(b)





Supplementary Table I: Characteristics of CHOK1SV and GS-CHOK1SV cell lines in 
fed-batch suspension culture.  The data presented was generated from cell lines revived from 
the same frozen stocks as analyzed in this study.  CHO refers to the non-transfected CHOK1SV 
host and Null8 is a ÒnullÓ cell line constructed using an empty GS vector (see section 2.2).  All 
cell lines were cultured in 10 L airlift reactors, with the exception of Z1 and Z14 which were 
cultured in 2 L shake flasks.  Airlift reactors were operated as a direct scale down of industrial 
manufacturing conditions. Data supplied by Tracy Root and Alison Porter (Lonza Biologics, 
Slough). The GS-CHOK1SV cell lines expressing cB72.3 are arranged by qmAb rank order. 
 








[Product]              
at harvest          
(µg/mL) 
qmAb             
(pg/cell.h) 
CHO 6.50 1408 N/A N/A 
Null 8 9.50 1790 N/A N/A 
Z1 12.00 2254 162 0.100 
41 12.63 2533 364 0.154 
54 8.05 1784 480 0.300 
Z14 11.10 2295 870 0.400 
53 18.69 3869 1464 0.450 
142 18.25 3928 1629 0.480 
114 12.44 2275 1312 0.640 
38 15.90 3145 2221 0.770 
147 11.25 2582 1964 0.801 





















Figure 1: GS-CHOK1SV cell line LB01 grown in varying amounts of MSX. Duplicate batch 
suspension cultures supplemented with 0, 25, 50 and 75 µM MSX were sub-cultured every 96 h.  
Following 1344 h total GCL expression was determined by qPCR and western blot. MSX 
concentration is plotted against the normalised amounts of GCLc (A) and GCLm (B) mRNA 
determined by qPCR (Mean ± SD).  Protein extracts were separated by 1D-PAGE and blotted 
with antibodies for GCLc, GCLm, and β-Actin (C, D and E). Normalised amounts of GCLc and 
GCLm protein were determined by densitometric analysis of the bands (F-G respectively). 
 
Figure 2: The effect of MSX on growth and productivity of cell line LB01 in fed batch 
suspension culture.  Fed batch suspension culture of lineages supplemented with 0, 25, 50 and 
75 µM MSX for 1344 h total culture time (Figure 1) were completed. L-MSX concentration is 
plotted against IVC (A), qmAb (B), secreted mAb concentration (C) from fed batch cultures. 
GCLc and GCLm normalized mRNA and protein amounts plotted against IVC (D, G, J and M), 
qmAb (E, H, K and N) and secreted concentrations of cB72.3 (F, I, L and O) respectively for 
individual fed-batch suspension cultures performed from cryopreserved cells following MSX 
supplementation. 
 
Figure 3: Inhibition of GCL in batch suspension culture. GS-CHOK1SV cell line 42 was 
cultured in 100 mL cultures and supplemented with 0 to 5 mM BSO. To ensure that only 
endogenously derived GSH from the GCL pathway was available to the cell, the GS-CHO cell 
line used for this work (cell line: 42) was adapted to and cultured in a medium formulation 
lacking GSH and MSX.  100mL cultures were supplemented with BSO at concentrations 
selected to give partial inhibition (20 to 100 µM) together with enzyme-inhibitor saturation 
concentrations (250 µM to 5 mM) based on the data reported by Clark et al. (1984).
36
  Viable 
cell concentration (black full lines) and culture viability (grey dashed lines) were monitored 
over 288 h. Supernatant samples were removed at 288 h for quantification of the amount of 
secreted cB72.3 by Protein A HPLC. 
 
Figure 4: The effect of BSO on growth and productivity of cell line 42 in batch suspension 
culture. 30 mL cultures in GSH free medium were supplemented with 0 to 5000 µM BSO and 
grown in batch suspension mode over 288 h. Conditions predicted to give partial (pa) and full 
(fu) inactivation of GCL activity are shown based on Clarke et al.
36
).  Viable cell concentration 
(Figure 3) and Mean cell diameter (A) were monitored using a Vi-Cell (Beckman Coulter, UK). 
The integral viable cell concentration (IVC) was determined for each culture (B).  Supernatant 
was removed at harvest (288 h) and subsequently analysed for the presence of cB72.3 (C) by 
Protein A HPLC.  qmAb was then determined for each culture (D). 
 
Figure 5: Ero1-Lα redox shift assay. GS-CHOK1SV cells in suspension were untreated (0 µM 
BSO) or treated with 20, 100 and 250 µM BSO. In addition reduced (10 mM DTT) and oxidized 
(10 mM DPS) controls were included. All cell samples were treated with a membrane 
permeable alkylating agent to freeze redox status following treatment with AMS to determine 
any change in migration relative to redox controls following SDS and western blot analysis with 




Supplementary Figure 1: Comparison of the amounts of GCL mRNA and protein in GS-
CHOK1SV cells lines and the CHOK1SV host.  Samples were removed from batch 
suspension cultures after 96 h of culture time. CHO A and CHO B are replicate	 cultures	 of	
CHOK1SV	 host.	 	 (A) GCLc and (B) GCLm subunit mRNA amounts as determined by qRT-
PCR, for 7 GS-CHOK1SV cell lines expressing cB72.3, CHOK1SV host and Null 8. Data 
shown are the mean of experimental replicates ± SD (n=3).  (C) Western blot analysis of GCL 
subunits and GS in the CHOK1SV host, Null 8 and 5 GS-CHOK1SV cell lines expressing 
cB72.3. Protein extracts were separated by 1D-PAGE and western blotted, the blots were 
probed with antibodies for GCLc, GCLm, GS and β-Actin. (D-F) Amounts of GCLc, GCLm 
and GS proteins as determined by densitometric analysis of the relevant bands observed on the 
western blot (Figure 1C). All numercial data presented in Figures A, B and 1D-F have been 
normalized to CHOK1SV replicate A (CHO-A).   
 
Supplementary Figure 2: Mean GSH concentrations in CHOK1SV host and GS-
CHOK1SV cell lines.  Samples were removed from batch suspension cultures of CHOK1SV 
host (CHO) and GS-CHOK1SV cell lines 54, 114, 53, 142 and 38 after 96 h of culture time.  
GSH concentration was subsequently determined using the GSH-Glo kit (Promega, UK) 
according to manufacturerÕs instructions.  Data are the mean of two independent samples from 
the same culture ± SD.    
 
Supplementary Figure 3: The effect of MSX on growth and productivity of cell lines Z1 
and Z14 in fed batch suspension culture.  Fed batch suspension culture of lineages 
supplemented with 0, 25, 50 and 75 µM MSX for 1344 h total culture time were completed. L-
MSX concentration is plotted against IVC (A (Z1), D (Z14)), qmAb (B (Z1), E (Z14)), secreted 
mAb concentration (C (Z1), F (Z14)) from fed batch cultures for cells lines Z1 and Z14. 
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